Pfizer's strong Q4 2024 results showcase growth in cancer drugs and Vyndaqel sales. Learn why PFE stock is a top pick for ...

Pfizer (NYSE: PFE) has been around for 175 years, but the company's revenue soared to its highest ever only in more recent ...

Pfizer's robust R&D pipeline is expected to drive future growth and offset patent expirations. Read why I maintain my buy ...

Pfizer (NYSE: PFE) has hit a bit of a rough patch, after doing well with its COVID vaccine and Paxlovid treatment. The ...

Baby boomers looking to set up their portfolios for a relaxing and rewarding retirement have plenty of factors to consider.

Pfizer's Earnings Growth And 8.7% ROE When you first look at it, Pfizer's ROE doesn't look that attractive. We then compared the company's ROE to the broader industry and were disappointed to see ...

Merck’s Keytruda may be the most talked about drug facing loss of exclusivity but it’s far from the only one, as several of ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Large American pharmaceutical companies are showing a distinct trend never seen before: they are increasingly looking for ...

We recently published a list of 10 Best Very Cheap Stocks To Buy Right Now. In this article, we are going to take a look at where Pfizer Inc.

Pfizer's Earnings Growth And 8.7% ROE When you first look at it, Pfizer's ROE doesn't look that attractive. We then compared the company's ROE to the broader industry and were disappointed to see that ...